Signal from the log
HighLife
80 M€ · France · Medtech
HighLife remplace la valve mitrale par un cathéter passé dans l'artère fémorale, sans ouvrir le thorax. Elle vise les patients en insuffisance mitrale modérée à sévère que ni la chirurgie ni la réparation bord à bord ne peuvent traiter. Marquage CE obtenu en janvier 2026, étude pivot en cours aux États-Unis.
Verified
Announced on , logged by the watch of 22 September 2026.
- Operation
- Funding round
- Announced amount
- 80 M€
- Country
- France
- Sector
- Medtech
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
Led by Andera Partners , Sofinnova Partners , Supernova Invest , Mérieux Equity Partners , with Capricorn Partners
What is missing before publishing
- The stage of the round is not disclosed. A letter is never inferred from an amount or a track record.
Provenance
Source maddyness,sifted
Logged on 22 September 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.